Compare
Opko Health, Inc. vs TG Therapeutics, Inc. vs Organogenesis Holdings Inc. vs HUTCHMED (China) Ltd
| Latest fiscal year | Opko Health, Inc. OPK | TG Therapeutics, Inc. TGTX | Organogenesis Holdings Inc. ORGO | HUTCHMED (China) Ltd HCM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $606.88M | $616.29M | $564.17M | $548.51M |
| Revenue growth (YoY) | -14.9% | +87.3% | +17.0% | -13.0% |
| Gross margin | 33.9% | 83.7% (computed) | n/a | 38.7% (computed) |
| Operating margin | -19.3% | 20.0% | 7.9% | -7.1% |
| Net margin | -37.2% | 72.6% | 6.6% | 83.3% |
| Net income | -$225.68M | $447.18M | $37.03M | $456.91M |
| EPS (Diluted) | -$0.30 | $2.77 | $0.15 | $0.52 |
| Operating cash flow | -$178.54M | -$24.77M | -$10.31M | -$64.66M |
| Free cash flow | -$190.82M | -$24.99M | -$24.46M | -$78.81M |
| Cash & equivalents | $364.41M | $79.15M | $93.68M | $71.33M |
| Total assets | $1.93B | $1.06B | $598.73M | $1.75B |
| Total liabilities | $663.99M | $415.23M | $164.81M | $501.83M |
| Shareholders' equity | $1.27B | $648.02M | $300.13M | $1.25B |
| Return on year-end equity | -17.8% | 69.0% | 12.3% | 36.5% |
| Shares outstanding | n/a | 155.31M | 126.95M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Opko Health, Inc. | TG Therapeutics, Inc. | Organogenesis Holdings Inc. | HUTCHMED (China) Ltd |
|---|---|---|---|---|
| Latest | $606.88M Ended 2025-12-31 | $616.29M Ended 2025-12-31 | $564.17M Ended 2025-12-31 | $548.51M Ended 2025-12-31 |
| 1 year earlier | $713.14M Ended 2024-12-31 | $329.00M Ended 2024-12-31 | $482.04M Ended 2024-12-31 | $630.20M Ended 2024-12-31 |
| 2 years earlier | $863.50M Ended 2023-12-31 | $233.66M Ended 2023-12-31 | $433.14M Ended 2023-12-31 | $838.00M Ended 2023-12-31 |
| 3 years earlier | $1.00B Ended 2022-12-31 | $2.79M Ended 2022-12-31 | $450.89M Ended 2022-12-31 | $426.41M Ended 2022-12-31 |
| 4 years earlier | $1.77B Ended 2021-12-31 | $6.69M Ended 2021-12-31 | $467.36M Ended 2021-12-31 | $356.13M Ended 2021-12-31 |